Cardiol Therapeutics

Cardiol Therapeutics is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The company's lead product, CardiolRxTM, is a pharmaceutically produced oral cannabidiol formulation being investigated in a Phase II/III outcomes study (LANCER trial). The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in hospitalized COVID-19 patients with a prior history of or risk factors for CVD.